BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Patient Worthy - ECPv5.12.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Patient Worthy
X-ORIGINAL-URL:https://patientworthy.com
X-WR-CALDESC:Events for Patient Worthy
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210807T120000
DTEND;TZID=America/New_York:20210807T130000
DTSTAMP:20260626T110029
CREATED:20210408T140351Z
LAST-MODIFIED:20210408T140351Z
UID:1067332-1628337600-1628341200@patientworthy.com
SUMMARY:The MDS Foundation's Outcomes for High-Risk MDS Patients Undergoing Transplant vs. Standard Non-Transplant Therapies Webinar
DESCRIPTION:Outcomes for High-Risk MDS Patients Undergoing Transplant vs. Standard Non-Transplant Therapies\nAugust 7\, 2021 \nSpeaker: Erica D. Warlick\, MD\, University of Minnesota Medical Center \nThis free webinar provides an overview of allogeneic hematopoietic cell transplant as a treatment for high-risk MDS. This approach will be compared with other common treatment approaches\, such as hypomethylating agents and other novel agents. \nTo register\, click here.
URL:https://patientworthy.com/event/mds-foundations-outcomes-high-risk-transplant-therapies/
CATEGORIES:Myelodysplastic Syndromes
ORGANIZER;CN="The%20MDS%20Foundation":MAILTO:patientliaison@mds-foundation.org
END:VEVENT
END:VCALENDAR